概述规格名称和识别符技术文档高级数据产品属性关联靶点（人）质检证书（CoA,COO,BSE/TSE 和分析图谱) 化学和物理性质安全和危险性（GHS）此产品的引用文献技术文档和文章引用文献溶液计算器

🧪

为什么选择此级别

Moligand™ 级，适用于对基线干扰要求严格的色谱和分析工作流程。

🌡

储存与运输

-80℃储存。特低温运输。请查阅批次 COA 获取详细规格。

📋

质量文档

SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。

📚

文献证明

在色谱分析、有机合成和交叉偶联反应领域已被 35 篇同行评审文献引用。

概述

易溶于氯仿，溶于丙酮，微溶于甲醇，不溶于水。

Information

Lovastatin (MK-803) Lovastatin (MK-803, Mevinolin) is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM in a cell-free assay, used for lowering cholesterol (hypolipidemic agent). Lovastatin triggers autophagy .
In vitro

Lovastatin inhibits LPS- and cytokine-mediated production of NO and expression of iNOS in rat primary astrocytes. Lovastatin inhibits LPS-induced expression of TNF-alpha, IL-1beta, and IL-6 in rat primary astrocytes, microglia, and macrophages. Lovastatin results in over 95% inhibition of DNA synthesis as measured by incorporation of [3H]thymidine into DNA. Lovastatin synchronizes cells in the G1 and not in the G0 phase of the cell cycle. Lovastatin has a similar growth-inhibitory activity against ras-dependent as well as ras-independent cell lines. Lovastatin produces a profound reduction of apolipoprotein-B-containing lipoproteins, especially LDL cholesterol and, to a lesser extent, plasma triglyc- erides, and a small increase in HDL cholesterol. Lovastatin arrests cells by inhibiting the proteasome, which results in the accumulation of p21 and p27, leading to G1 arrest. Lovastatin is an inhibitor of hydroxymethyl glutaryl (HMG)-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Lovastatin can be used to arrest cultured cells in the G1 phase of the cell cycle, resulting in the stabilization of the cyclin-dependent kinase inhibitors (CKIs) p21 and p27. Lovastatin (2-10 mM) arrests cells in G1 and also prolonged--or arrested a minor fraction of cells in--the G2 phase of the cell cycle in human bladder carcinoma T24 cell line expressing activated p21ras. Lovastatin (50 mM) is cytotoxic in human bladder carcinoma T24 cell line expressing activated p21ras.

In vivo

Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥98%

规格

英文别名

Mevinolin | (2S)-2-methyl-butanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester

规格或纯度

Moligand™, 10mM in DMSO

英文名称

Lovastatin (MK-803)

生化机理

洛伐他汀（MK-803，Mevinolin）是一种 HMG-CoA 还原酶抑制剂，在无细胞试验中的 IC50 值为 3.4 nM，用于降低胆固醇（降血脂药）。洛伐他汀会引发自噬。

储存条件

-80℃储存

运输条件

特低温运输

作用类型

激活剂

名称和识别符

EC号

692-955-0

分子类型

小分子

Isomeric SMILES

CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C

分子量

404.54

Reaxy-Rn

14572691

Reaxys-RN link address

https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=14572691&ln=

技术文档

📋 安全数据表 (SDS)

全面的危险、操作、储存及法规合规文件。

下载 SDS →

✅ 分析证书 (COA)

批次质量数据。输入批号以获取对应 COA。

查询 COA →

📊 产品数据表

产品规格和应用的快速参考摘要。

查看数据表 →

🔬 规格说明书

该级别的完整质量属性和验收标准。

查看规格说明 →

高级数据

产品属性

ALogP	4.3

关联靶点（人）

HMGCR Tclin 3-羟基-3-甲基戊二酰辅酶A还原酶(3-hydroxy-3-methylglutaryl-coenzyme A reductase) (23 活性数据)

点击查看靶蛋白信息： HMGCR

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

化学和物理性质

溶解性

Solubility (25°C) In vitro

比旋光度

320 ° (C=0.5, CH3CN)

熔点

175°C

安全和危险性（GHS）

象形图

GHS08, GHS07

信号词

Danger

危险声明

H351: 怀疑引起遗传缺陷

H302: 吞食有害

H317: 可能引起皮肤过敏反应

H372: 通过长时间或反复暴露对器官造成损害

H361: 怀疑破坏生育力或未出生的孩子

预防措施声明

P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾

P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。

P302+P352: 如皮肤沾染：用水充分清洗。

P321: 特殊处理（请参阅此标签上的...）。

P405: 密闭存放

P501: 将内容物/容器处理到。。。

P264: 处理后要彻底洗手。

P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。

P270: 使用本产品时，请勿进食、饮水或吸烟。

P272: 被污染的工作服不允许离开工作场所

P333+P313: 如发生皮肤刺激或皮疹：求医/就诊。

P362+P364: 脱掉沾污的衣服，清洗后方可重新使用。

P330: 漱口

P203: 使用前，获取、阅读并遵守所有安全说明。

P301+P317: 如果被吞咽：请寻求医疗帮助。

P318: 如果暴露或担心，请就医。

P319: 如果你感到不适，请寻求医疗帮助。

WGK Germany

RTECS

EK7907000

Merck Index

5586

个人防护装备

Eyeshields,Gloves,type N95 (US),type P1 (EN143) respirator filter

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

技术文档和文章

他汀类抗高血脂抗癌药物

目录：技术文章

探索主题:

抗癌抗高血脂药物治疗

Statins Antihyperlipidemics Anticancer Agents

目录：技术文章

探索主题:

Anti-cancer Anti-hyperlipidemia Drug treatment

ADME/Tox 研究入门与进阶：代谢酶、转运体及典型工具化合物解析

目录：技术文章

探索主题:

ADME/Tox

ADME/Tox: From Basics to Advanced – Metabolizing Enzymes, Transporters and Key Tool Compounds

目录：技术文章

探索主题:

ADME/Tox

青刺果油对皮肤屏障的保护与潜在修护机制：脂肪酸组成、表皮脂质代谢及研究证据

目录：技术文章

探索主题:

青刺果油青刺果籽油亚油酸油酸棕榈酸硬脂酸

Protective and Potential Reparative Mechanisms of Prinsepia utilis Seed Oil on the Skin Barrier: Fatty Acid Composition, Epidermal Lipid Metabolism, and Research Evidence

目录：技术文章

探索主题:

Seed Oil Prinsepia Utilis Seed Oil

血脂异常的代谢机制、新兴干预靶点与药物研究进展

目录：技术文章

探索主题:

siRNA 反义寡核苷酸动脉粥样硬化血脂异常低密度脂蛋白胆固醇 PCSK9 脂蛋白（a） APOC3 ANGPTL3 脂蛋白脂酶

Metabolic Mechanisms, Emerging Therapeutic Targets, and Advances in Drug Research for Dyslipidemia

目录：技术文章

探索主题:

siRNA Lipoprotein(a) Antisense oligonucleotide atherosclerosis PCSK9 APOC3 ANGPTL3 dyslipidemia low-density lipoprotein cholesterol lipoprotein lipase

YAP/TAZ–TEAD为何成为Hippo通路新的突破口？

目录：技术文章

探索主题:

肿瘤靶向 YAP TAZ TEAD Hippo NF2 TEAD棕榈酰化机械传导

Why Have YAP/TAZ–TEAD Become a New Breakthrough Point in the Hippo Pathway?

目录：技术文章

探索主题:

mechanotransduction YAP TAZ TEAD Hippo NF2 tumor targeting TEAD palmitoylation

此产品的引用文献

如何在您的发表作品中引用阿拉丁的产品和网站? 引用文献检索

引用文献

1. Mengdi Zhang, Zhaoxin Wang, Siyu Hao, Lei Hao, Xinying Zhang, Peng Yu, Hua Sun. (2020) Synthesis of natural 3′-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, [PMID:32791402] [10.1016/j.ejmech.2020.112649]
2. Gai Gao, Jie Zhao, Jing Ding, Shuyan Liu, Yanyan Shen, Changxin Liu, Huifen Ma, Yu Fu, Jiangyan Xu, Yiran Sun, Xiaowei Zhang, Zhenqiang Zhang, Zhishen Xie. (2023) Alisol B regulates AMPK/mTOR/SREBPs via directly targeting VDAC1 to alleviate hyperlipidemia. PHYTOMEDICINE, [PMID:38520833] [10.1016/j.phymed.2023.155313]
3. Xiang Li, Rongxia Li, Xueyu Wang, Xinying Zhang, Zhiyi Xiao, Haibo Wang, Wenhui Sun, Hao Yang, Peng Yu, Qing Hu, Qinghui Guo, Hua Sun. (2023) Effects and mechanism of action of Chrysanthemum morifolium (Jinsi Huangju) on hyperlipidemia and non-alcoholic fatty liver disease. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, [PMID:37099836] [10.1016/j.ejmech.2023.115391]
4. Xiaoyi Shi, Meng Li, Qiming Huang, Liuming Xie, Zhibing Huang. (2023) Monacolin K Induces Apoptosis of Human Glioma U251 Cells by Triggering ROS-Mediated Oxidative Damage and Regulating MAPKs and NF-κB Pathways. ACS Chemical Neuroscience, [PMID:36917811] [10.1021/acschemneuro.3c00104]
5. Bo Wei, Yuanfang Li, Meiying Ao, Wenxiang Shao, Kun Wang, Tong Rong, Yun Zhou, Yong Chen. (2022) Ganglioside GM3-Functionalized Reconstituted High-Density Lipoprotein (GM3-rHDL) as a Novel Nanocarrier Enhances Antiatherosclerotic Efficacy of Statins in apoE−/− C57BL/6 Mice. Pharmaceutics, 14 (11): (2534). [PMID:36432725] [10.3390/pharmaceutics14112534]
6. Qing Sun, Li Li, Quan Zhou. (2022) Effects of Ethanolic Extract of Schisandra sphenanthera on the Pharmacokinetics of Rosuvastatin in Rats. Drug Design Development and Therapy, [PMID:35607596] [10.2147/DDDT.S364234]
7. Pan Zhenzhen, Wang Kai, Wang Xiniao, Jia Zhirong, Yang Yuqi, Duan Yalei, Huang Lianzhan, Wu Zhuo-Xun, Zhang Jian-ye, Ding Xuansheng. (2022) Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression. Molecular Cancer, 21 (1): (1-17). [PMID:35303882] [10.1186/s12943-022-01547-3]
8. Ping-Ting Xiao, Yu-Jia Kuang, Shi-Yu Liu, Zhi-Shen Xie, Jin-Hua Hao, E-Hu Liu. (2022) The antihyperlipidemic equivalent combinatorial components from peel of Citrus reticulata ‘Chachi’. JOURNAL OF FOOD AND DRUG ANALYSIS, [PMID:35647727] [10.38212/2224-6614.3388]
9. Bei Yan, Lei Chen, Yanhui Wang, Jiacheng Zhang, Hui Zhao, Qinglian Hua, Shengjie Pei, Zihang Yue, Hui Liang, Huaqi Zhang. (2022) Preventive Effect of Apple Polyphenol Extract on High-Fat Diet-Induced Hepatic Steatosis in Mice through Alleviating Endoplasmic Reticulum Stress. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, [PMID:35227062] [10.1021/acs.jafc.1c07733]
10. Zhishen Xie, Er-wen Li, Gai Gao, Yueyue Du, Mengyao Wang, Hui Wang, Pan Wang, Yonghui Qiao, Yunfang Su, Jiangyan Xu, Xiaowei Zhang, Zhenqiang Zhang. (2022) Zexie Tang targeting FKBP38/mTOR/SREBPs pathway improves hyperlipidemia. JOURNAL OF ETHNOPHARMACOLOGY, [PMID:35151834] [10.1016/j.jep.2022.115101]
11. Andy Wijaya, Yi Wang, Dan Tang, Yuan Zhong, Boyan Liu, Meng Yan, Quhui Jiu, Wei Wu, Guixue Wang. (2021) A study of lovastatin and L-arginine co-loaded PLGA nanomedicine for enhancing nitric oxide production and eNOS expression. Journal of Materials Chemistry B, 10 (4): (607-624). [PMID:34994373] [10.1039/D1TB01455B]
12. Longkai Shi, Emad Karrar, Xingguo Wang. (2021) Sesamol ameliorates hepatic lipid accumulation and oxidative stress in steatosis HepG2 cells via the PPAR signaling pathway. JOURNAL OF FOOD BIOCHEMISTRY, 45 (11): (e13976). [PMID:34664288] [10.1111/jfbc.13976]
13. Hong Zhang, Shaoting Sang, Huimin Xu, Linghua Piao, Xiande Liu. (2021) Lovastatin suppresses bacterial therapy-induced neutrophil recruitment to the tumor by promoting neutrophil apoptosis. Journal of Functional Foods, [10.1016/j.jff.2021.104693]
14. Ying Xu, Yunxia Dong, Cong Wang, Qian Jiang, Haichao Chu, Yue Tian. (2021) Lovastatin attenuates sevoflurane-induced cognitive disorder in aged rats via reducing Aβ accumulation. NEUROCHEMISTRY INTERNATIONAL, [PMID:34048842] [10.1016/j.neuint.2021.105078]
15. Ping-Ting Xiao, Zhi-Shen Xie, Yu-Jia Kuang, Shi-Yu Liu, Chun Zeng, Ping Li, E-Hu Liu. (2021) Discovery of a potent FKBP38 agonist that ameliorates HFD-induced hyperlipidemia via mTOR/P70S6K/SREBPs pathway. Acta Pharmaceutica Sinica B, [PMID:34900535] [10.1016/j.apsb.2021.03.031]
16. Na Deng, Ziqian He, Ruixue Guo, Bisheng Zheng, Tong Li, Rui Hai Liu. (2020) Highland Barley Whole Grain (Hordeum vulgare L.) Ameliorates Hyperlipidemia by Modulating Cecal Microbiota, miRNAs, and AMPK Pathways in Leptin Receptor-Deficient db/db Mice. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, [PMID:32985184] [10.1021/acs.jafc.0c04780]
17. Xing Zhang, Wen Shi, Hui He, Ruge Cao, Tao Hou. (2020) Hypolipidemic effects and mechanisms of Val-Phe-Val-Arg-Asn in C57BL/6J mice and 3T3-L1 cell models. Journal of Functional Foods, [10.1016/j.jff.2020.104100]
18. Guihua Yan, Yunchao Feng, Zhebang Gao, Xianhai Zeng, Wenjing Hong, Wenjie Liu, Yong Sun, Xing Tang, Tingzhou Lei, Lu Lin. (2019) Stable and Biocompatible Cellulose-Based CaCO3 Microspheres for Tunable pH-Responsive Drug Delivery. ACS Sustainable Chemistry & Engineering, [10.1021/acssuschemeng.9b05144]
19. Kun Wang, Chuan Yu, Yang Liu, Wendiao Zhang, Yanan Sun, Yong Chen. (2018) Enhanced Antiatherosclerotic Efficacy of Statin-Loaded Reconstituted High-Density Lipoprotein via Ganglioside GM1 Modification. ACS Biomaterials Science & Engineering, [PMID:33418777] [10.1021/acsbiomaterials.7b00871]
20. Yu Zhang, Shiguo Chen, Chaoyang Wei, Jianchu Chen, Xingqian Ye. (2016) Proanthocyanidins from Chinese bayberry (Myrica rubra Sieb. et Zucc.) leaves regulate lipid metabolism and glucose consumption by activating AMPK pathway in HepG2 cells. Journal of Functional Foods, [10.1016/j.jff.2016.12.030]
21. Zu-Guo Zheng, Ya-Ping Zhou, Xin Zhang, Pyone Myat Thu, Zhi-Shen Xie, Chong Lu, Tao Pang, Bin Xue, Da-Qian Xu, Yan Chen, Xiao-Wei Chen, Hui-Jun Li, Xiaojun Xu. (2016) Anhydroicaritin improves diet-induced obesity and hyperlipidemia and alleviates insulin resistance by suppressing SREBPs activation. BIOCHEMICAL PHARMACOLOGY, [PMID:27816546] [10.1016/j.bcp.2016.10.016]
22. Zhi-Shen XIE, Ling-Jun ZHONG, Xiao-Meng WAN, Meng-Ning LI, Hua YANG, Ping LI, Xiao-Jun XU. (2016) Petroleum ether sub-fraction of rosemary extract improves hyperlipidemia and insulin resistance by inhibiting SREBPs. Chinese Journal of Natural Medicines, [PMID:28236404] [10.1016/S1875-5364(16)30089-9]
23. Junfeng Li, Min Guo, Cuiping Yuan, Tiezhu Li, Jie Zhang, Li Ren. (2024) Ameliorative potential of ellagic acid via PPARγ against hyperlipidemia: Insights from mice and zebrafish. Food Bioscience, [10.1016/j.fbio.2024.105582]
24. Jie Zhao, Gai Gao, Jing Ding, Wei Liu, Tao Wang, Liang Zhao, Jiangyan Xu, Zhenqiang Zhang, Xiaowei Zhang, Zhishen Xie. (2024) Astragaloside I Promotes Lipophagy and Mitochondrial Biogenesis to Improve Hyperlipidemia by Regulating Akt/mTOR/TFEB Pathway. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, [PMID:39226078] [10.1021/acs.jafc.4c03172]
25. Qiuyan Jiang, Tiehua Zhang, Yuan Liang, Jie Zhang. (2024) Baicalein ameliorates lipid accumulation in HepG2 cells via the pregnane X receptor signaling pathway. Food Bioscience, [10.1016/j.fbio.2024.104482]
26. Lin Fu, Hengxin Ren, Chaoxing Wang, Yaxin Zhao, Bohang Zou, Xiangyu Zhang. (2025) Formation of PEG-PLGA Microspheres for Controlled Release of Simvastatin and Carvacrol: Enhanced Lipid-Lowering Efficacy and Improved Patient Compliance in Hyperlipidemia Therapy. Polymers, 17 (5): (574). [PMID:40076067] [10.3390/polym17050574]
27. Kun Miao, Yawei Zhao, Ning Xue. (2024) Gkongensin A, an HSP90β inhibitor, improves hyperlipidemia, hepatic steatosis, and insulin resistance. Heliyon, [PMID:38655315] [10.1016/j.heliyon.2024.e29367]
28. Guangjie Zhang, Huiying Zhang, Ruiyi Dong, Hongmei Zhao, Junfeng Li, Weiming Yue, Zheng Ma. (2024) Oleanolic acid attenuates obesity through modulating the lipid metabolism in high-fat diet-fed mice. Food Science & Nutrition, [PMID:39479652] [10.1002/fsn3.4408]
29. Zijun Tao, Jian Zhang, Fuge Niu, Huien Zhang, Zhongfa Chen, Shanfu Wang, Yuli Zhang, Jie Li, Peng Liu. (2024) Polygonati rhizoma fermentation by Monascus ruber and evaluation of fermentation products in vitro. PROCESS BIOCHEMISTRY, [10.1016/j.procbio.2024.07.013]
30. Peiyu Xue, Xinyong You, Li Ren, Weiming Yue, Zheng Ma. (2024) PPARγ-mediated amelioration of lipid metabolism abnormality by kaempferol. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, [PMID:39278305] [10.1016/j.abb.2024.110154]
31. Qian Hu, Mengyao Wang, Meng Chen, Jinjin Wang, Ting Niu. (2025) Toosendanin Induces Cell Cycle Arrest and Apoptosis to Suppress Diffuse Large B-Cell Lymphoma Growth by Inhibiting PI3Kα/β and PLK1 Signaling. PHYTOTHERAPY RESEARCH, [PMID:39949030] [10.1002/ptr.8439]
32. Yuan-yuan Zhai, Qiang Wang, Qi-yao Nong, Mei-yu Gao, Ying Zhang, Qin-wen Xiao, Yuan Tian, Zun-jian Zhang, Feng-guo Xu, Pei Zhang. (2025) Pitavastatin overcomes multi-drug resistance in CRC and NSCLC by targeting the NRP1-ZFX axis. BIOCHEMICAL PHARMACOLOGY, [PMID:40684995] [10.1016/j.bcp.2025.117183]
33. Li Haihua, Li Jiahe, Liu Ningjin, Li Huishan, Wang Jiarui, Zhang Rulan, Xue Jingyan, Kang Xiaotian, Guan Xinying, Lin Shiya, Zhang Ziyu, Kuang Jiaqi, Qian Chenlei, Zhou Pengfei. (2025) Synergistic enhancement of alkaloid biosynthesis in Catharanthus roseus CMCs via enzyme Inhibition and abiotic elicitation. PLANT CELL TISSUE AND ORGAN CULTURE, 162 (3): (1-12). [10.1007/s11240-025-03211-2]
34. Jiaxuan Li, Yu Li, Xunyu Song, Yuxiao Wang, Yinxu Zhang, Xinghua Gao, Mingqian Tan, Wentao Su. (2025) Ulva lactuca Extracellular Vesicles Protect Against High-Fat Diet-Induced Intestinal Damage via Nrf2/Keap1/HO-1 Activation. Food & Function, [PMID:41355512] [10.1039/D5FO03126E]
35. Liu Shu-yan, Zhang Xiao-wei, Gao Gai, Liu Chang-xin, Chen Hui, Fu Zhong-xue, Xu Jiang-yan, Wang Zhen-zhen, Zhang Zhen-qiang, Xie Zhi-shen. (2025) Pseudolaric Acid B Alleviates Non-alcoholic Fatty Liver Disease by Targeting PPARα to Regulate Lipid Metabolism and Promote Mitochondrial Biogenesis. Chinese Journal of Integrative Medicine, [PMID:40515882] [10.1007/s11655-025-3832-y]